Brian Halbert is an Oncology physician affiliated with Ochsner Medical Center. OpenAlex indexes 35 publications with 578 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
5 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
27.2%Phenothiazine6.4%Prochlorperazine Maleate100%Part D≥41 patientsOpioid Agonist5%Oxycodone Hcl61%Morphine Sulfate Er39%Part D≥21 patients+ 6 more classes in this area
Metabolism & gastrointestinal
26.5%Corticosteroid12%Prednisone100%Part D≥40 patientsSerotonin-3 Receptor Antagonist6.1%Ondansetron Hcl80%Ondansetron Odt20%Part D≥50 patients+ 4 more classes in this area
Cancer & immunology
18.4%Cytochrome P450 17A1 Inhibitor9.8%Abiraterone Acetate100%Part D≥22 patientsAnti-androgens4.8%Nubeqa52%Erleada48%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of lutetium Lu 177 vipivotide tetraxetan on prostate cancer outcomes by race.
Journal of Clinical Oncology
2026 - HSR26-245: Association of Health-Related Quality of Life (HRQoL) With Overall Survival in Pancreatic Ductal Adenocarcinoma (PDAC)
Journal of the National Comprehensive Cancer Network
2026 - Financial toxicity in patients with newly diagnosed pancreatic cancer: A prospective cohort study.
JCO Oncology Practice
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Lawrence Blonde, MD
Ochsner Medical Center
Hector Ventura, MD
Ochsner Medical Center
George Pankey, MD
Ochsner Medical Center
Tyrone Collins, MD
Ochsner Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”